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The increasing importance of chemotherapy in cancer management has resulted in the appearance of several new agents but the problem of poor selectivity and host toxicity still remains. Of these newer agents doxorubicin has been widely tested but its use and possibly its efficacy is limited by cardiac toxicity. Several analogues of doxorubicin have been produced in attempts to resolve this problem. One of these, 4'epi-doxorubicin (4'epiDX), has been shown to have less cardiac toxicity than the parent compound (Natale et al., 1981; Casazza et al., 1978) . Its anti-tumour activity and plasma kinetics in animals have also been reported by several authors (Bonf4nte et al., 1979 (Bonf4nte et al., , 1980 Casazza et al., 1978; Benjamin et al., 1977) . Little human data are available on this agent so this study was designed to determine its distribution and pharmacokinetics in patients.
Eight patients who were to be operated on for proven disease received an i.v. bolus of 4'epiDX (kindly supplied by Farmitalia Carlo Erba, Milan, Italy) 2h before surgery. Four patients (Group A) received 10mgm-2, 4 patients (Group B) received 20mg m -2 over 60-90 sec, followed by 500 ml saline. Ninety min later, patients received 0.5mg atropine sulphate and 10mg benzodiazepine i.m. in preparation for a general anaesthetic after a further 30 min.
Specimens were collected without interfering with surgical procedures and small amounts of either biopsy material or excised organs were immediately frozen at -200. All tissues were examined by the pathologist and collection time varied between 2-4 h depending upon the surgery. The HPLC method of Moro et al. (1981) was modified to determine the anthracycline concentration in tissues (Moro, personal communication) ; 50ngml-1 4-demethoxydaunorubicin (Farmitalia-Carlo Erba) was used as an internal standard in the homogenized specimen. It has been shown that 4'epiDX disappears more rapidly from serum than doxorubicin (Bonfante et 650 -al., 1979) and that between 2-4 h after 600 . administration the circulating concentration is only -10% of the peak 5-min value (Bonfante et al., C 550 1979; Benjamin et al., 1974) . Very little is found in 0 500 * urine (Rosso et al., 1972) , suggesting a rapid tissue distribution similar to that of doxorubicin (Donelli o 450 et al., 1979) . in animal tissues (Bonfante et al., 1979) . The H 300 primary excretion of anthracyclines appears to be 250 _ through hepatic metabolism and biliary clearance (Benjamin et al., 1974; Broggini et al., 1980) (Chan et al., 1978; Broggini et al., 1980) and may explain the low haematological toxicity observed (Natale et al., 1981) . The level of 4'epiDX found in muscle was less than that found for doxorubicin (Broggini et al., 1980) and could explain the minor cardiac toxicity.
In conclusion, it appears that the distribution of anthracyclines is mainly due to blood flow and hepatic clearance, in agreement with the literature. Certain selective patterns are seen that cannot be accounted for by vascularisation and there is some evidence to suggest higher concentrations in tumour tissue. The importance of minor metabolism and the influence of necrotic material will need to be determined before a more definite statement can be made on the advantages of 4'epiDX over its parent compound, doxorubicin.
